Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide

NCT05060627 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Relapsed Multiple Myeloma

Interventions

DRUG: Belantamab mafodotin
DRUG: Carfilzomib
DRUG: Dexamethasone

Sponsor

PETHEMA Foundation

Collaborators

[object Object]